Accéder au contenu
Merck

The Wolbachia endosymbiont of Brugia malayi has an active phosphoglycerate mutase: a candidate target for anti-filarial therapies.

Parasitology research (2008-12-02)
Jeremy M Foster, Sylvine Raverdy, Mehul B Ganatra, Paul A Colussi, Christopher H Taron, Clotilde K S Carlow
RÉSUMÉ

Phosphoglycerate mutases (PGM) interconvert 2- and 3-phosphoglycerate in the glycolytic and gluconeogenic pathways. A putative cofactor-independent phosphoglycerate mutase gene (iPGM) was identified in the genome sequence of the Wolbachia endosymbiont from the filarial nematode, Brugia malayi (wBm). Since iPGM has no sequence or structural similarity to the cofactor-dependent phosphoglycerate mutase (dPGM) found in mammals, it may represent an attractive Wolbachia drug target. In the present study, wBm-iPGM cloned and expressed in Escherichia coli was mostly insoluble and inactive. However, the protein was successfully produced in the yeast Kluyveromyces lactis and the purified recombinant wBm-iPGM showed typical PGM activity. Our results provide a foundation for further development of wBm-iPGM as a promising new drug target for novel anti-filarial therapies that selectively target the endosymbiont.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Acide D-(−)-3-phosphoglycérique disodium salt, ≥93% dry basis (enzymatic), powder
Sigma-Aldrich
Enolase from baker′s yeast (S. cerevisiae), lyophilized powder, ≥50 units/mg protein
Sigma-Aldrich
Pyruvate Kinase from rabbit muscle, Type VII, buffered aqueous glycerol solution, 350-600 units/mg protein